Alana F Ogata1,2,3, Adam M Maley1,2,3, Connie Wu1,2,3, Tal Gilboa1,2,3, Maia Norman1,2,4, Roey Lazarovits1,2, Chih-Ping Mao1, Gail Newton1, Matthew Chang5, Katrina Nguyen5, Maliwan Kamkaew5, Quan Zhu5,6, Travis E Gibson1,3, Edward T Ryan7,6,8, Richelle C Charles7,6, Wayne A Marasco5,6, David R Walt1,2,3. 1. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 2. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA. 3. Harvard Medical School, Boston, MA, USA. 4. Tufts University School of Medicine, Boston, MA, USA. 5. Department of Cancer Immunology and Virology Dana-Farber Cancer Institute, Boston, MA, USA. 6. Department of Medicine, Harvard Medical School, Boston, MA, USA. 7. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. 8. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston MA, USA.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 21 million people worldwide since August 16, 2020. Compared to PCR and serology tests, SARS-CoV-2 antigen assays are underdeveloped, despite their potential to identify active infection and monitor disease progression. METHODS: We used Single Molecule Array (Simoa) assays to quantitatively detect SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens in the plasma of coronavirus disease (COVID-19) patients. We studied plasma from 64 COVID-19 positive patients, 17 COVID-19 negative patients, and 34 pre-pandemic patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we quantified changes in 31 SARS-CoV-2 biomarkers in 272 longitudinal plasma samples obtained for 39 COVID-19 patients. Data were analyzed by hierarchical clustering and were compared to longitudinal RT-PCR test results and clinical outcomes. RESULTS: SARS-CoV-2 S1 and N antigens were detectable in 41 out of 64 COVID-19 positive patients. In these patients, full antigen clearance in plasma was observed a mean ± 95%CI of 5 ± 1 days after seroconversion and nasopharyngeal RT-PCR tests reported positive results for 15 ± 5 days after viral antigen clearance. Correlation between patients with high concentrations of S1 antigen and ICU admission (77%) and time to intubation (within one day) was statistically significant. CONCLUSIONS: The reported SARS-CoV-2 Simoa antigen assay is the first to detect viral antigens in the plasma of COVID-19 positive patients to date. These data show that SARS-CoV-2 viral antigens in the blood are associated with disease progression, such as respiratory failure, in COVID-19 cases with severe disease.
BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 21 million people worldwide since August 16, 2020. Compared to PCR and serology tests, SARS-CoV-2 antigen assays are underdeveloped, despite their potential to identify active infection and monitor disease progression. METHODS: We used Single Molecule Array (Simoa) assays to quantitatively detect SARS-CoV-2spike, S1 subunit, and nucleocapsid antigens in the plasma of coronavirus disease (COVID-19) patients. We studied plasma from 64 COVID-19 positive patients, 17 COVID-19 negative patients, and 34 pre-pandemic patients. Combined with Simoa anti-SARS-CoV-2 serological assays, we quantified changes in 31 SARS-CoV-2 biomarkers in 272 longitudinal plasma samples obtained for 39 COVID-19patients. Data were analyzed by hierarchical clustering and were compared to longitudinal RT-PCR test results and clinical outcomes. RESULTS:SARS-CoV-2 S1 and N antigens were detectable in 41 out of 64 COVID-19 positive patients. In these patients, full antigen clearance in plasma was observed a mean ± 95%CI of 5 ± 1 days after seroconversion and nasopharyngeal RT-PCR tests reported positive results for 15 ± 5 days after viral antigen clearance. Correlation between patients with high concentrations of S1 antigen and ICU admission (77%) and time to intubation (within one day) was statistically significant. CONCLUSIONS: The reported SARS-CoV-2 Simoa antigen assay is the first to detect viral antigens in the plasma of COVID-19 positive patients to date. These data show that SARS-CoV-2 viral antigens in the blood are associated with disease progression, such as respiratory failure, in COVID-19 cases with severe disease.
Authors: Andrew J Rivnak; David M Rissin; Cheuk W Kan; Linan Song; Matthew W Fishburn; Tomasz Piech; Todd G Campbell; Derek R DuPont; Melissa Gardel; Sean Sullivan; Brian A Pink; Carlos G Cabrera; David R Fournier; David C Duffy Journal: J Immunol Methods Date: 2015-05-07 Impact factor: 2.303
Authors: P Koraka; C Suharti; T E Setiati; A T Mairuhu; E Van Gorp; C E Hack; M Juffrie; J Sutaryo; G M Van Der Meer; J Groen; A D Osterhaus Journal: J Clin Microbiol Date: 2001-12 Impact factor: 5.948
Authors: Lorena Ivana Spinsanti; Adrián Alejandro Farías; Juan Javier Aguilar; María del Pilar Díaz; Marta Silvia Contigiani Journal: Arch Virol Date: 2011-06-19 Impact factor: 2.574
Authors: Fatima Amanat; Daniel Stadlbauer; Shirin Strohmeier; Thi H O Nguyen; Veronika Chromikova; Meagan McMahon; Kaijun Jiang; Guha Asthagiri Arunkumar; Denise Jurczyszak; Jose Polanco; Maria Bermudez-Gonzalez; Giulio Kleiner; Teresa Aydillo; Lisa Miorin; Daniel S Fierer; Luz Amarilis Lugo; Erna Milunka Kojic; Jonathan Stoever; Sean T H Liu; Charlotte Cunningham-Rundles; Philip L Felgner; Thomas Moran; Adolfo García-Sastre; Daniel Caplivski; Allen C Cheng; Katherine Kedzierska; Olli Vapalahti; Jussi M Hepojoki; Viviana Simon; Florian Krammer Journal: Nat Med Date: 2020-05-12 Impact factor: 53.440
Authors: Maia Norman; Tal Gilboa; Alana F Ogata; Adam M Maley; Limor Cohen; Evan L Busch; Roey Lazarovits; Chih-Ping Mao; Yongfei Cai; Jun Zhang; Jared E Feldman; Blake M Hauser; Timothy M Caradonna; Bing Chen; Aaron G Schmidt; Galit Alter; Richelle C Charles; Edward T Ryan; David R Walt Journal: Nat Biomed Eng Date: 2020-09-18 Impact factor: 25.671
Authors: Hui Chen; Zhao Li; Sheng Feng; Melissa Richard-Greenblatt; Emily Hutson; Stefen Andrianus; Laurel J Glaser; Kyle G Rodino; Jianing Qian; Dinesh Jayaraman; Ronald G Collman; Abigail Glascock; Frederic D Bushman; Jae Seung Lee; Sara Cherry; Alejandra Fausto; Susan R Weiss; Hyun Koo; Patricia M Corby; Alfonso Oceguera; Una O'Doherty; Alfred L Garfall; Dan T Vogl; Edward A Stadtmauer; Ping Wang Journal: Clin Chem Date: 2021-12-30 Impact factor: 8.327
Authors: Lael M Yonker; Tal Gilboa; Alana F Ogata; Yasmeen Senussi; Roey Lazarovits; Brittany P Boribong; Yannic C Bartsch; Maggie Loiselle; Magali Noval Rivas; Rebecca A Porritt; Rosiane Lima; Jameson P Davis; Eva J Farkas; Madeleine D Burns; Nicola Young; Vinay S Mahajan; Soroush Hajizadeh; Xcanda I Herrera Lopez; Johannes Kreuzer; Robert Morris; Enid E Martinez; Isaac Han; Kettner Griswold; Nicholas C Barry; David B Thompson; George Church; Andrea G Edlow; Wilhelm Haas; Shiv Pillai; Moshe Arditi; Galit Alter; David R Walt; Alessio Fasano Journal: J Clin Invest Date: 2021-07-15 Impact factor: 14.808
Authors: Arun Richard Chandrasekaran; Molly MacIsaac; Javier Vilcapoma; Clinton H Hansen; Darren Yang; Wesley P Wong; Ken Halvorsen Journal: Nano Lett Date: 2021-01-04 Impact factor: 11.189